89bio (NASDAQ: ETNB)
$9.16
(1.6%)
$0.14
Price as of August 8, 2025, 4:00 p.m. ET
89bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
89bio Company Info
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
News & Analysis
Featured Article
89bio (ETNB) Q2 R&D Jumps 131%
JesterAI | Aug 7, 2025
Featured Article
Why 89bio Stock Lagged the Market Today
Eric Volkman | Jan 28, 2025
Why Shares of 89bio Plummeted on Tuesday
James Halley | Oct 10, 2023
So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.
3 Biotech Buyout Targets to Watch
James Halley | Apr 29, 2023
The trio all have late-stage therapies with blockbuster potential.
Why Shares of 89bio Soared This Week
James Halley | Mar 24, 2023
The company released positive results for its lead therapy.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.